Patents by Inventor Thor Ostenfeld

Thor Ostenfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR TREATING PAIN
    Publication number: 20240026036
    Abstract: The disclosure provides novel methods and dosage regimens for use in treating or preventing pain, wherein the binding molecule comprises an NGF antagonist domain and a TNF? antagonist domain, wherein the NGF antagonist domain is an anti-NGF antibody or an antigen-binding fragment thereof and wherein the TNF? antagonist domain comprises a soluble TNF? binding fragment of TNFR.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 25, 2024
    Inventors: FRASER WELSH, THARANI CHESSELL, KEITH TAN, THOR OSTENFELD, RICHARD JENKINS
  • SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1
    Publication number: 20230121578
    Abstract: The present application relates to compounds of formula (I?) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).
    Type: Application
    Filed: September 7, 2022
    Publication date: April 20, 2023
    Inventors: Johan Bartholomeus, Roland Bürli, Rebecca Jarvis, Shawn Johnstone, Thor Ostenfeld, Ina Terstiege, Massimiliano Travagli, Stephane Turcotte
  • Small molecule modulators of the BTB domain of Keap1
    Patent number: 11479539
    Abstract: The present application relates to compounds of formula (I?) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 25, 2022
    Assignee: MedImmune Limited
    Inventors: Johan Bartholomeus, Roland Bürli, Rebecca Jarvis, Shawn Johnstone, Thor Ostenfeld, Ina Terstiege, Massimiliano Travagli, Stephane Turcotte
  • SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1
    Publication number: 20210094931
    Abstract: The present application relates to compounds of formula (I) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).
    Type: Application
    Filed: December 20, 2018
    Publication date: April 1, 2021
    Inventors: Johan Bartholomeus, Roland Bürli, Rebecca Jarvis, Shawn Johnstone, Thor Ostenfeld, Ina Terstiege, Massimiliano Travagli, Stephane Turcotte